Study Confirms Link Between Atypical Femur Fractures and Fosamax Use

Ennis & Ennis, PA Summarizes the Latest Fosamax Study that Confirms Long-Term Use of Biphosphonates, such as Fosamax and Boniva, Causes Atypical Femur Fractures (PRWEB) May 26, 2012 After the New England Journal of Medicine published their findings that use of biphosphonates is not deemed beneficial outside of a 3 to 5 year window, the Archives of Internal Medicine have confirmed that prolonged use of the drug increases risk for atypical fractures of the femur. Commonly used brand names of the drug are Fosamax, Reclast, Boniva, and Actonel. In the past few years the FDA has increased t
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations